Compare Funko Inc (FNKO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Funko Inc trades at $5.88 (market cap $315.21M), while Regeneron Pharmaceuticals Inc trades at $678.67 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 221× Funko Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | REGN | |
|---|---|---|
Market Cap | $315.21M | $69.66B |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $812.27 |
52-Week Low | $2.46 | $542.52 |
Enterprise Value | $560.25M | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.785, up 4.23% today, with a bullish technical signal from moving averages. The stock shows improving revenue trends, with Q1 2026 sales reaching $200.9M, beating expectations, though net income remains negative. Analyst consensus is split between Buy and Hold, with no Sell ratings. Recent news highlights new product launches and strong collectibles demand, supporting a positive sentiment shift.
Outlook: FNKO presents a speculative opportunity with recent earnings beats and revenue growth, but risks include persistent net losses and high debt. Investors should weigh the bullish technicals and product momentum against fundamental weaknesses in profitability and cash flow volatility.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
